Searchable abstracts of presentations at key conferences in endocrinology

ea0029oc4.3 | Pituitary Basic | ICEECE2012

miR-26a targets PRKCD in ACTH pituitary adenoma

Gentilin E. , Tagliati F. , degli Uberti E. , Zatelli M.

MicroRNAs (miRNAs) have several physiological functions, but have been also implicated in human neoplastic initiation and progression. We previously demonstrated that 30 miRNAs are differentially expressed in normal human pituitary as compared to pituitary adenomas. However, the most of miRNAs target genes remain unknown, hindering the understanding of the miRNAs contribute to pituitary tumorigenesis.The aims of this study were to: (i) validate a murine ...

ea0029oc9.2 | Endocrine Tumours & Translation | ICEECE2012

GH protects breast cancer cells from chemotherapy by blocking cytotoxic-induced apoptosis in estrogen receptor negative breast cancer cells

Minoia M. , Gentilin E. , Mole D. , Tagliati F. , Ambrosio M. , degli Uberti E. , Zatelli M.

Context: GH and insulin-like growth factor (IGF1) play important roles in breast cancer (BC) development. IGF1 has been shown to importantly influence estrogen effects on BC, suggesting that estrogen receptors (ER) may mediate also GH effects. We previously demonstrated that GH and IGF1 protect the ER positive BC-derived MCF7 cell line towards the cytotoxic effects of doxorubicin (D), independently of IGF1.Aim of the study: Evaluate whether this holds tr...

ea0029p800 | Endocrine tumours and neoplasia | ICEECE2012

Effects of mTOR inhibitors in the control of non functioning pituitary adenomas cell growth

Minoia M. , Gentilin E. , Rossi M. , Tagliati F. , degli Uberti E. , Zatelli M.

Introduction: The main therapeutic approach for non functioning pituitary adenomas (NFA) is surgery, since radiotherapy has several important side effects and medical therapy is rarely effective. Therefore, understanding the molecular pathways regulating NFA cell proliferation is crucial for future drug development. We here explore the possible role of mTOR inhibitors, Everolimus and BEZ235 (which also inhibits the PI3 K pathway) on the effects of Insulin-like Growth Factor-1 ...

ea0026p180 | Neuroendocrinology | ECE2011

Targeting PKC in human pancreatic neuroendocrine tumor cells

Mole D , Gagliano T , Gentilin E , Bondanelli M , Tagliati F , degli Uberti E , Zatelli M C

The currently curative therapy for pancreatic endocrine tumours (PET), accounting for <3% of pancreatic tumors, is complete surgical resection, which is achieved in the minority of cases. Most tumors are diagnosed in a late stage, especially in endocrine-inactive forms, indicating the need for further medical therapy. The serine–threonine protein kinase C (PKC) family plays central regulatory roles in several cellular processes, including cell proliferation. PKC signa...

ea0011p461 | Endocrine tumours and neoplasia | ECE2006

Role of complex Cdk4/Cyclin D1 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro

Tagliati F , Zatelli MC , Bottoni A , Piccin D , Luchin A , Culler MD , degli Uberti EC

Somatostatin (SRIH) inhibits cell proliferation by interacting with five distinct SRIH receptor subtypes (SSTR) by several pathways in many tissues. We previously demonstrated that SRIH, by activating SHP-1, inhibits cell proliferation of the human Medullary Thyroid Carcinoma (MTC) cell line, TT, which expresses all SSTR. However, the effects of SRIH on cell cycle proteins have not been investigated, so far. We therefore investigated the effects of SRIH and of a selective SSTR...

ea0011p462 | Endocrine tumours and neoplasia | ECE2006

Selective Cyclo-oxygenase 2 inhibitors revert chemoresistance In Medullary thyroid carcinoma by a mechanism mediated by P-gp and PGH2

Zatelli MC , Luchin A , pICCIN D , Tagliati F , Bottoni A , Vignali C , Bondanelli M , degli Uberti EC

Medullary thyroid carcinoma (MTC) is a malignant tumour deriving from parafollicular C cells, with a highly chemoresistant phenotype. Failure of medical therapy has been ascribed, at least in part, to multi drug resistance (MDR1) gene over-expression. MDR1 encodes for a transmembrane glycoprotein, P-gp, which hampers intracellular accumulation of cytotoxic drugs. It has been demonstrated that P-gp expression and function depend on cyclo-oxygenase 2 (COX-2) expression, which is...

ea0029p783 | Endocrine tumours and neoplasia | ICEECE2012

Bronchial carcinoid response to mTOR inhibitors depends on mTOR expression levels

Gagliano T. , Rossi R. , Mole D. , Gentilin E. , Minoia M. , Tagliati F. , degli Uberti E. , Zatelli M.

Introduction: Bronchial carcinoids (BCs), originating from endocrine cells dispersed in the respiratory epithelium, can be divided into typical (TBC) and atypical (ABC). TBC are less aggressive, smaller, and much less likely to metastasize, while ABC are more aggressive and metastasize. mTOR has a central role in regulating cell growth, metabolism, and apoptosis. A differential mTOR activation in BCs has been previously demonstrated, suggesting that mTOR pathway might play a p...

ea0026p181 | Neuroendocrinology | ECE2011

GH enhances breast cancer chemoresistance by inhibiting JNK-mediated apoptosis

Minoia M , Gentilin E , Tagliati F , Mole D , Ambrosio M R , Baroni A , degli Uberti E , Zatelli M C

GH and insulin-like growth factor 1 (IGF1) are known to promote breast carcinogenesis. Breast cancer (BC) incidence in not increased in female acromegalic patients, but mortality is greater as compared to general population. We previously demonstrated that GH/IGF1 excess influences BC response to therapy, possibly accounting for the increased mortality. We indeed showed that GH and IGF1 induce cell proliferation of a BC cell line, the MCF7 cells, providing protection towards t...

ea0026p486 | Thyroid cancer | ECE2011

mTOR inhibition hampers cell viability in selected human medullary thyroid carcinoma primary cultures

Filieri C , Zatelli M C , Minoia M , Tagliati F , Buratto M , Ambrosio M R , Pelizzo M , degli Uberti E C

It has been demonstrated that everolimus, an mTOR inhibitor, has potent anti-proliferative effect in a human Medullary Thyroid Carcinoma (MTC) cell line, TT, and in two human MTC primary cultures. We aimed at evaluating the possible antiproliferative effects of everolimus in a group of 20 human MTC in primary culture. To this purpose, 20 MTCs were dispersed in primary cultures, treated without or with 1 nM – 1 μM everolimus, 10 nM SOM230, and/or 50 nM IGF1. Cell viab...